Biomarin Pharmaceutical (BMRN) Profit After Tax (QoQ) (2009 - 2026)
Biomarin Pharmaceutical (BMRN) Profit After Tax (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Biomarin Pharmaceutical | 11.65 Bn | 9.42 Bn | 571.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 326.58% |
| Dec 31, 2025 | -51.49% |
| Sep 30, 2025 | -117.39% |
| Jun 30, 2025 | -4.78% |
| Mar 31, 2025 | 48.62% |
| Dec 31, 2024 | 48.86% |
| Sep 30, 2024 | -37.84% |
| Jun 30, 2024 | 52.29% |
| Mar 31, 2024 | 335.15% |
| Dec 31, 2023 | -49.54% |
| Sep 30, 2023 | -16.13% |
| Jun 30, 2023 | 9.43% |
| Mar 31, 2023 | 17,769.48% |
| Dec 31, 2022 | 96.26% |
| Sep 30, 2022 | -114.15% |
| Jun 30, 2022 | -61.08% |
| Mar 31, 2022 | 308.64% |
| Dec 31, 2021 | -58.65% |
| Sep 30, 2021 | -621.49% |
| Jun 30, 2021 | -81.83% |